The European Commission’s Directorate General for Enterprise and Industry granted Teva a Marketing Authorization for its human G-CSF product, Tevagrastim®.
- Our Awards
- Our Capabilities
- Our People
- Blog
- BioBlast®
- E-Books
- AU – Patent Case Review 2024
- AU – Patent Case Review 2023
- AU – Patent Case Review 2022
- AU – Patent Case Review 2021
- AU – Pharmaceutical Patent Term Extensions (PTE) in Australia
- AU – Patent Linkage in Australia and New Zealand
- NZ – Patent Litigation in New Zealand
- Patent Re-Examination in New Zealand
- AU – Australia’s Rocket Patent Register: From Application to Patent in a Few Months
- AU – Entering National Phase in Australia
- AU – Exclusive Licences
- AU – Patent Litigation in Australia
- AU | US | EU – The one-minute guide to life sciences patent eligibility in the US, Europe and Australia
- AU – Patent Re-Examination in Australia
- AU – The 2-Minute Guide to Australian Patent Oppositions
- AU – Trade Mark Oppositions
- Webinars
- Diversity
- Careers
- Contact Us
